Comparative Pharmacology
Head-to-head clinical analysis: DEPO SUBQ PROVERA 104 versus MICRONOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO SUBQ PROVERA 104 versus MICRONOR.
DEPO-SUBQ PROVERA 104 vs MICRONOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, thereby inhibiting ovulation and causing endometrial thinning.
Progestin-only contraceptive; suppresses ovulation by inhibiting gonadotropin release, thickens cervical mucus, and alters endometrial lining to prevent implantation.
104 mg subcutaneously every 3 months (13 weeks). Administer into the anterior thigh or abdomen by a healthcare professional.
0.35 mg orally once daily, taken at the same time each day.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours (range 20-80 hours) with chronic administration due to slow absorption from the depot; clinically, this allows for once-weekly dosing.
Terminal elimination half-life is approximately 5-14 hours (mean 7.6-8.7 hours). In clinical context, the short half-life requires daily dosing for contraceptive efficacy.
Primarily metabolized in the liver; metabolites are excreted in urine (70-80%) and feces (20-30%). Less than 1% unchanged in urine.
Approximately 50-80% of a dose is excreted in urine as glucuronide and sulfate conjugates of norethindrone and its metabolites; about 20-40% is excreted in feces via biliary elimination.
Category C
Category C
Progestin-Only Contraceptive
Progestin-Only Contraceptive